Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100en_US
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorGholami, Mohammad Hossein
dc.contributor.authorHashemi, Farid
dc.contributor.authorZabolian, Amirhossein
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2021-11-08T07:15:26Z
dc.date.available2021-11-08T07:15:26Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractP-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1?, miRNAs, and long noncoding (lnc)RNAs, to reveal their participation in DOX resistance. These antitumor compounds and genetic tools synergistically reduce P-gp expression. Furthermore, ATP depletion impairs P-gp activity to enhance the antitumor activity of DOX. Nanoarchitectures, including liposomes, micelles, polymeric nanoparticles (NPs), and solid lipid nanocarriers, have been developed for the co-delivery of DOX with anticancer compounds and genes enhancing DOX cytotoxicity. Surface modification of nanocarriers, for instance with hyaluronic acid (HA), can promote selectivity toward cancer cells. We discuss these aspects with a focus on P-gp expression and activity. © 2021 The Author(s)en_US
dc.identifier.citationMirzaei, S., Gholami, M. H., Hashemi, F., Zabolian, A., Farahani, M. V., Hushmandi, K., ... & Orive, G. (2021). Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today.10.1016/j.drudis.2021.09.020.en_US
dc.identifier.doi10.1016/j.drudis.2021.09.020en_US
dc.identifier.endpage20en_US
dc.identifier.issn1359-6446en_US
dc.identifier.pmid34624510en_US
dc.identifier.scopus2-s2.0-85117840070en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1016/j.drudis.2021.09.020
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2203
dc.identifier.wosWOS:000750040900008en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofDrug Discovery Todayen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleAdvances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospectsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
229.pdf
Boyut:
3.41 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu